Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives

Oncol Lett. 2021 Nov;22(5):809. doi: 10.3892/ol.2021.13070. Epub 2021 Sep 27.ABSTRACTPancreatic cancer has a dire prognosis and will represent the second leading cause of cancer death in the next 10 years. The multifactorial approach represents one of the main issues in controlling the extension of this neoplasm. In recent years, the characteristics of the tumor microenvironment, metastasis mechanisms and the relationship between immune system and neoplastic cells have been described, which has made it possible to understand the pathophysiology of pancreatic adenocarcinoma. Currently, there is a failure to provide an effective preventive method or early detection, so patients present with an advanced stage at the time of diagnosis. Despite numerous efforts, little progress has been made in clinical outcome and in improving survival in long term. Therefore, in the recent years, diverse diagnostic tests, treatments and possible approaches have been developed in the fields of radiotherapy, chemotherapy and surgery to find a combination of them that improves life expectancy in patients diagnosed with pancreatic cancer. At the moment, numerous clinical trials are being conducted to evaluate preventive diagnostic procedures such as serological markers or perfecting available imaging tests. On the other hand, implementation of immunotherapy is being studied in a neoplasm that has lagged in the application of this procedure since present possible treatments do not substantially impro...
Source: Oncology Letters - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

World J Gastroenterol. 2021 Oct 28;27(40):6775-6793. doi: 10.3748/wjg.v27.i40.6775.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor with high lethality. Even with surgery, radiotherapy, chemotherapy, and other locoregional or systemic therapies, the survival rates for PDAC are low and have not significantly changed in the past decades. The special characteristics of the PDAC's microenvironment and its complex immune escape mechanism need to be considered when designing novel therapeutic approaches in this disease. PDAC is characterized by chronic inflammation with a high rate of tumor-associated macro...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Immunotherapy | Pancreas | Pancreatic Cancer | Study